|
An HIV Vaccine Preparedness Study Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about An HIV Vaccine Preparedness Study conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. An HIV Vaccine Preparedness Study Clinical research trials and An HIV Vaccine Preparedness Study medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like An HIV Vaccine Preparedness Study. An HIV Vaccine Preparedness Study Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a An HIV Vaccine Preparedness Study clinical trial. Test subjects typically obtain the finest healthcare available for their An HIV Vaccine Preparedness Study condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > An HIV Vaccine Preparedness Study  An HIV Vaccine Preparedness Study
An HIV Vaccine Preparedness Study
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this study is to estimate the rate at which a certain population becomes infected with HIV. The individuals examined in this study are people who are expected to take part in future studies of HIV vaccines and nonvaccine HIV prevention studies. This study also examines the chances of becoming HIV-positive based on certain risk factors under conditions that are similar to the conditions that would exist in HIV vaccine and non-HIV prevention studies. Before studying the effectiveness of a potential HIV vaccine, it is important to learn about the range of HIV risk behaviors in the potential participants of these studies. The probability of HIV infection associated with these risk behaviors should also be examined. This study is designed to increase the ability of HIVNET to put into place HIV prevention trials, to increase the diversity of trial participants, and to target populations at highest risk for HIV infection.
Details: Vaccine preparedness studies are necessary in order to prepare for launching preventive HIV vaccine efficacy trials. It is important to gather information on the risk of HIV infection among recruited populations, the extent and stability of HIV risk behaviors in these populations, and the risk of HIV infection associated with risk behaviors. This vaccine preparedness study is designed to expand the capacity of the HIVNET to implement HIV prevention trials, increase the diversity of its participant population, and further target populations at highest risk of HIV infection. Participants complete a total of 6 scheduled study visits: 2 at baseline, 2 at follow-up 6 months later, and 2 at follow-up 12 months after enrollment. Participant risk behaviors and knowledge of and attitudes toward HIV vaccine and other HIV prevention trials are assessed at each time point. HIV infection status is tested by standard HIV ELISA and Western blot at follow-up, as well as at participant request throughout the study. Participants are instructed to recognize and report suspected primary HIV infection based on symptoms or high-risk exposures. HIV pre-test, risk reduction, and post-test counseling is provided in accordance with CDC standards of practice. Participants who become infected with HIV during the study are counseled and referred for medical and psychosocial services.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Participants meet the following criteria: - HIV-seronegative. - Available for 6 months of the study. (Note: - Participants who plan to move from one study location to another are eligible.) - Willing and able to provide information for locator purposes. - Report one or more of the following risk behaviors: For men: - Intravenous or intramuscular injection of any drug on an average of 3 or more days per week during the last 3 months. - Anal intercourse (receptive or insertive) with one or more other men in the last year. For women: - Intravenous or intramuscular injection of any drug on an average of 3 or more days per week during the last 3 months. - Having a current male sex partner who is infected with HIV. - Having a current male sex partner who has injected drugs in the last 5 years. - Having 5 or more male sex partners in the last year. - Diagnosis of syphilis, chlamydia, gonorrhea, first episode herpes, pelvic inflammatory disease, and/or trichomoniasis in the last year. - Exchange of sex for money or drugs in the last year. -Use of crack cocaine in the last 12 months. See General Inclusion Criteria for required risk behaviors. Volunteers must be: - HIV-positive through HIVNET testing or HIV-seronegative by EIA. - Presently in a sexual relationship of at least 6 months duration with the intention to remain with this partner for the duration of the study. - Willing to identify and recruit this sexual partner to which he/she has disclosed or will disclose HIV serostatus. - Willing to receive counseling and HIV testing (HIV-seronegative partners only). - Willing to agree to be interviewed with their partner and individually. - Willing to continue engaging in sex with their partner. - Willing to participate in a couples-based condom promotion intervention. - Willing and able to attend each scheduled intervention/follow-up study visit. Exclusion Criteria Co-existing Condition: Persons with the following symptoms or conditions are excluded: - An obvious psychological or psychiatric disorder that would preclude provision of informed consent or otherwise contraindicate study participation. - Any condition which in the opinion of the principal investigator would interfere with achieving the study objectives. Men at risk through anal intercourse only are excluded if they: - Currently have a single HIV-seronegative partner with whom they have been in a mutually monogamous relationship for at least 2 years. Men and women at risk through injection only are excluded if they: - Have been participating in any methadone drug treatment program for at least the last 6 months. - Currently obtain over 50 percent of needles/syringes for injection of drugs from a needle exchange program. NOTE: - Meeting the following extremely high injection risk criteria overrides the exclusion criteria for injection risk as outlined above: - Using a needle or syringe after one or more known HIV-positive persons 2 or more times in the past 3 months. - Using a needle or syringe after persons of unknown HIV status in the past 3 months provided the following two conditions are true: - (1) report using a needle or syringe after someone else 2 or more different times in the past 3 months and (2) report using a needle or syringe after 3 or more different persons in the past 3 months. (This second criterion could be met in 3 episodes of injection with a single injection partner, if the participant used a needle or syringe after a different person each time. Alternatively, the criterion could be met in a single episode of injection, if the participant used a needle or syringe after 3 or more persons had used a single set of works.) Concurrent Medication: Excluded: - Enrollment in an HIV vaccine trial, unless approval is obtained from the Data Management Committee Project Officer. Risk Behavior: - See General Exclusion Criteria for excluded risk behaviors.
Total Enrollment: 4892
Location and Contact Information:
Overall Study Official:
DaveMetzger, Study Chair,
Bronx Lebanon Hosp Ctr
Bronx, New York, 10456
United States
Miriam Hosp
Providence, Rhode Island, 02906
United States
New York Blood Ctr
Bronx, New York, 10456
United States
Los Angeles County / Health Research Assoc / Drew Med Ctr
Los Angeles, California, 90059
United States
Johns Hopkins Univ
Baltimore, Maryland, 21205
United States
New York Univ Med Ctr
New York City, New York, 10016
United States
Univ of Illinois Hosp at Chicago
Chicago, Illinois, 60612
United States
Univ of Pennsylvania / HIVNET
Philadelphia, Pennsylvania, 19104
United States
Additional Information:
Study ID Numbers: HIVNET D01;
Study Start Date:
Record last reviewed: March 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000915
Other Hiv Infections Studies:
1. Safety of the Candidate Vaccine C4-V3 Alone or with Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy
2. The Safety and Effectiveness of bis-POM PMEA in HIV-Infected Patients
3. Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV Infection
4. Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV
5. A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success with or Who Cannot Take Other Treatments for VZV
Related Studies:
Other HIV Infections Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
An HIV Vaccine Preparedness Study
|
|
|
|
|
|
|
|
